Case of bullous pemphigoid induced by apatinib mesylate

Zheng, Qi; Ma, Yuelong; Shen, Fang; Wang, Qingliang; Song, Xun; Jiang, Weiping; Xie, Sai‐Sai

doi:10.1111/bcp.14583

Cited by 6 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, radical surgery is the protocol of choice for the treatment of breast cancer, and aggressive postoperative chemotherapy is essential to prevent tumor recurrence and metastasis. Apatinib mesylate is an oral antiangiogenic targeted drug that blocks VEGFR-2 to suppress the proliferation of vascular endothelial cells by reducing the activation of mitogenic protein kinase (MAPK) to achieve antitumor effects [7][8][9]. In addition, Traditional Chinese medicine (TCM) treatment can be used as an adjuvant treatment for breast cancer to reduce the side effects and adverse effects of radiotherapy, chemotherapy, and endocrine therapy, thereby regulating the immune function and physical condition of patients [10].…”

Section: Introductionmentioning

confidence: 99%

Effects of Apatinib Mesylate Monotherapy on the Incidence of Adverse Reactions and Immune Function in Patients with Breast Cancer after Radical Mastectomy

Lin

Zang

2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. To assess the effects of monotherapy with apatinib mesylate on the incidence of adverse events and immune function in breast cancer patients after a radical mastectomy. Methods. Between December 2018 and August 2020, 90 patients with breast cancer scheduled for a radical mastectomy in People’s Liberation Army Navy 971 Hospital were randomly recruited and assigned at a ratio of 1 : 1 to receive either conventional treatment (conventional group) or apatinib mesylate after radical mastectomy (study group). The primary endpoint was disease control rate (DCR), and the secondary endpoints were adverse events and the immune function of the patients. Results. Monotherapy with apatinib mesylate was associated with a higher DCR (86.67%) versus conventional postoperative treatment (42.23%). All patients in the study group had documented adverse events, including 2 (4.45%) cases of headache, 3 (6.67%) cases of dizziness, 9 (20.00%) cases of hypertension, 6 (13.34%) cases of hand-foot syndrome, 3 (6.67%) cases of thrombocytopenia, 1 (2.23%) case of tinnitus, 7 (15.56%) cases of fatigue, 2 (4.45%) cases of anemia, 2 (4.45%) cases of oral pain, and 10 (22.23%) cases of leukopenia. There were 23 cases of intermittent discontinuation due to adverse events during treatment, 15 cases of dose reduction, and 3 cases of discontinuation due to adverse events. The difference in preoperative and postoperative T-cell subsets and natural killer (NK) cells between the two groups did not come up to the statistical standard ( P > 0.05 ). Monotherapy with apatinib mesylate resulted in significantly lower levels of CD4+, CD4+/CD8+, and NK cells and higher CD8+ levels versus conventional treatment at 1 week and 4 weeks postoperatively ( P < 0.05 ). Conclusion. Apatinib mesylate monotherapy after radical mastectomy yields a high DCR, a lower incidence of adverse events, and improved immune recovery. Clinical trials are, however, required prior to clinical promotion.

show abstract

Section: Introductionmentioning

confidence: 99%

Effects of Apatinib Mesylate Monotherapy on the Incidence of Adverse Reactions and Immune Function in Patients with Breast Cancer after Radical Mastectomy

Lin

Zang

2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…The gingival lesions consist of inflammation and desquamation with irregular areas of ulcer caused by the rupture of blisters (24). The various literature reviews on BP are presented in Table II (7,(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36)(37)(38)(39)(40)(41)(42)(43).…”

Section: Cellular Immune Responsementioning

confidence: 99%

Recurrent bullous pemphigoid: A case report and literature review

et al. 2023

View full text Add to dashboard Cite

The present study aimed to enhance the current understanding of the etiopathogenesis, predisposing factors, clinical features and current management modalities for bullous pemphigoid (BP). BP is a chronic autoimmune disorder mediated by antibodies targeting BP180, a type XVII collagen (BPAG2), and BP230, a hemidesmosome protein located in basal keratinocytes, resulting in the formation of subepithelial blisters and multiple chronic oral ulcers, which heal without scarring, as well as urticarial lesions on the extremities. The BP lesions occur in the oral cavity following the onset of pruritic papules in the extremities. The present study describes the case of a patient with recurrent BP who was hypertensive and treated with amlodipine. In addition, a detailed search was performed on the PubMed database by searching the key word 'bullous pemphigoid'; ~33 articles were selected which were published from 2005-2022 for inclusion and discussion in the literature review. Studies published prior to 2005 were excluded. The anti-hypertensive drug, amlodipine, has a high propensity for BP lesions. However, caution needs to be taken when prescribing amlodipine for hypertension. The occurrence of BP must not be overlooked, and the oral physician must seek a complete detailed drug history and clinical examination, which will aid in the diagnosis of BP. BP lesions are usually multiple and have a chronicity and usually affects the oral mucosa, upper torso and arms. There is a period of exacerbations and remissions. On the whole, the present study provides insight into the etiology, predisposing risk factors, etiopathogenesis, clinical features and management modalities for BP.

show abstract

“…The cyano group is a widespread structural fragment distributed in many pharmaceutical compounds (Scheme 2a). [19][20][21][22][23][24] It is worth noting that the cyano group also serves as a versatile precursor for amino, carbonyl, and amide groups in organic transformation. [25][26][27][28][29] Most of the traditional cyanating reagents like metallic cyanides and TMSCN are highly toxic and environment-unfriendly.…”

Section: Introductionmentioning

confidence: 99%